1. Search Result
Search Result
Results for "

VEGFR Inhibitor

" in MedChemExpress (MCE) Product Catalog:

299

Inhibitors & Agonists

3

Screening Libraries

2

Fluorescent Dye

2

Biochemical Assay Reagents

5

Peptides

9

Inhibitory Antibodies

8

Natural
Products

29

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103002
    SU5408
    3 Publications Verification

    VEGFR2 Kinase Inhibitor I

    VEGFR Cardiovascular Disease
    SU5408 (VEGFR2 Kinase Inhibitor I) is a potent and cell-permeable inhibitor of VEGFR2 kinase with an IC50 of 70 nM.
    SU5408
  • HY-19986

    VEGFR Cardiovascular Disease Cancer
    IC50s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties .
    AAL993
  • HY-162326

    VEGFR Apoptosis Cancer
    VEGFR-2 IN-41 (Compound 8) is a VEGFR-2 inhibitor with IC50 0.0554 μM. VEGFR-2 IN-41 can induce apoptosis. VEGFR-2-IN-41 has antitumor activity .
    VEGFR-2-IN-41
  • HY-161025

    c-Fms VEGFR Cancer
    SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM .
    SYHA1813
  • HY-150027

    VEGFR PDGFR Cancer
    Multi-kinase-IN-3 (compound 2) is a potent angiokinase inhibitor. Multi-kinase-IN-3 shows inhibition activity against VEGFR-2 and PDGFRβ, with IC50 values of 58.3 and 55 nM, respectively .
    Multi-kinase-IN-3
  • HY-110272

    PTK787 succinate; ZK-222584 succinate; CGP-79787 succinate

    VEGFR Cancer
    Vatalanib (PTK787) succinate is a potent and orally active VEGFR inhibitor with IC50s of 37 nM, 77 nM, 270 nM, 660 nM, 730 nM, 1400 nM, and 580 nM for KDR, Flt-1, Flk, Flt-4, c-Kit, c-Fms, and PDGFR-β, respectively .
    Vatalanib succinate
  • HY-150026

    VEGFR PDGFR FGFR c-Kit Akt Src Apoptosis Cancer
    Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as LYN and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity .
    Multi-kinase-IN-2
  • HY-145849

    VEGFR Cancer
    VEGFR2-IN-1 is a potent and selective VEGFR2 inhibitor (IC50=19.8 nM). VEGFR2-IN-1 inhibits cell proliferation and migration through apoptosis activation and VEGFR2 inhibition .
    VEGFR2-IN-1
  • HY-147872

    VEGFR Microtubule/Tubulin Apoptosis Cancer
    VEGFR-2-IN-22 (Compound 25) is a dual VEGFR-2 and β-tubulin polymerization inhibitor with an IC50 of 19.82 nM against VEGFR-2. VEGFR-2-IN-22 induces apoptosis .
    VEGFR-2-IN-22
  • HY-144805

    VEGFR Apoptosis Cancer
    VEGFR-2-IN-18 (Compound 15d) is a potent VEGFR-2 inhibitor with an IC50 of 60 nM. VEGFR-2-IN-18 induces cell apoptosis. VEGFR-2-IN-18 shows antitumor activities .
    VEGFR-2-IN-18
  • HY-144804

    VEGFR Cancer
    VEGFR-2-IN-17 (Compound 15a) is a potent VEGFR-2 inhibitor with an IC50 of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities .
    VEGFR-2-IN-17
  • HY-149475

    VEGFR Cancer
    VEGFR-2-IN-33 (Compound 4d) is a VEGFR inhibitor (IC50: 61.04 nM). VEGFR-2-IN-33 inhibits HepG2 cell proliferation with an IC50 of 4.31 nM. VEGFR-2-IN-33 can be used for research of hepatocellular carcinoma (HCC) .
    VEGFR-2-IN-33
  • HY-148040

    VEGFR Cancer
    VEGFR-2-IN-29 (Compound 5) is a VEGFR-2 inhibitor with an IC50 of 16.5 nM .
    VEGFR-2-IN-29
  • HY-18926

    VEGFR2-IN-7 (compound E) is an inhibitor of VEGFR2. VEGFR2-IN-7 can used in study cancers .
    VEGFR2-IN-7
  • HY-151969

    VEGFR Cancer
    VEGFR-2-IN-30 is a VEGFR-2 inhibitor (IC50: 66 nM). VEGFR-2-IN-30 also inhibits PDGFR, EGFR and FGFR1 with IC50s of 180, 98, 82 nM respectively. VEGFR-2-IN-30 arrests cancer cell at S-phase and induces early and late apoptosis .
    VEGFR-2-IN-30
  • HY-144803

    VEGFR Cancer
    VEGFR-2-IN-16 (Compound 15b) is a potent VEGFR-2 inhibitor with an IC50 of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities .
    VEGFR-2-IN-16
  • HY-147902

    VEGFR Cancer
    VEGFR-2-IN-24 is a potent VEGFR-2 inhibitor with IC50 value of 0.22 µM. VEGFR-2-IN-24 can be used for tumor research .
    VEGFR-2-IN-24
  • HY-W800162

    VEGFR Cancer
    VEGFR-2-IN-37 (compound 12) is an inhibitor of VEGFR-2. The inhibition rate at 200 μM was approximately 56.9 μM. VEGFR-2-IN-37 is a potential inhibitor of human umbilical vein endothelial cell (HUVEC) proliferation .
    VEGFR-2-IN-37
  • HY-147779

    VEGFR Cancer
    VEGFR-2-IN-20 (Compound 7) is a potent inhibitor of VEGFR. VEGFR-2-IN-20 has the potential for the research of cancer diseases .
    VEGFR-2-IN-20
  • HY-147800

    VEGFR Cancer
    VEGFR-2-IN-21 (Compound 5d) is a potent VEGFR-2 inhibitor with an IC50 of 0.10 μM. VEGFR-2-IN-21 shows anticancer activity .
    VEGFR-2-IN-21
  • HY-146236

    VEGFR Cancer
    VEGFR-2-IN-27 (compound 7a) is a highly potent VEGFR-2 inhibitor with an IC50 value of 14.8 nM. VEGFR-2-IN-27 can be used for researching anticancer .
    VEGFR-2-IN-27
  • HY-19624

    ACC-789; ZK202650

    VEGFR PDGFR Cancer
    NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.
    NVP-ACC789
  • HY-145856

    VEGFR Apoptosis Cancer
    VEGFR-2-IN-11 (Compound 8h) is a potent VEGFR-2 inhibitor with an IC50 of 60.27 nM. VEGFR-2-IN-11 shows antitumor activity and induces cell apoptosis .
    VEGFR-2-IN-11
  • HY-146229

    VEGFR Cancer
    VEGFR-2-IN-25 (compound 5d) is a highly potent VEGFR-2 inhibitor with an IC50 value of 12.1 nM. VEGFR-2-IN-25 can be used for researching anticancer .
    VEGFR-2-IN-25
  • HY-153158

    VEGFR Cancer
    VEGFR2-IN-3 (compound 385) is a potent VEGFR2 inhibitor .
    VEGFR2-IN-3
  • HY-109020
    Acrizanib
    1 Publications Verification

    LHA510

    VEGFR Others
    Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2 .
    Acrizanib
  • HY-147926

    VEGFR Apoptosis Cancer
    VEGFR-2-IN-28 (compound 12c) is a potent VEGFR-2 inhibitor with IC50 value of 0.83 µM. VEGFR-2-IN-28 induces apoptosis and has anticancer activity .
    VEGFR-2-IN-28
  • HY-147133

    VEGFR Cancer
    VEGFR2-IN-2 (compound 6e) is a potent and selective VEGFR2 inhibitor with an IC50 of 19.32 nM. VEGFR2-IN-2 can be used for researching
    VEGFR2-IN-2
  • HY-155239

    VEGFR Cancer
    VEGFR-2-IN-35 (compound 7) is a potent VEGFR-2 inhibitor with IC50=37 nM. VEGFR-2-IN-35 inhibits MCF-7 and HCT 116 cancer cells with IC50 values of 10.56 and 7.07 μM, respectively .
    VEGFR-2-IN-35
  • HY-12060
    KRN-633
    3 Publications Verification

    VEGFR Cancer
    KRN-633 is a potent VEGFR inhibitor with IC50s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.
    KRN-633
  • HY-144795

    VEGFR Apoptosis Cancer
    VEGFR-2-IN-14 (Compound 5) is a potent VEGFR-2 inhibitor. VEGFR-2-IN-14 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis .
    VEGFR-2-IN-14
  • HY-157960

    VEGFR Cancer
    VEGFR-2-IN-42 (compound 8c) is a potent VEGFR-2 inhibitor. VEGFR-2-IN-42 shows anti-proliferative effect against MCF7 cells with the IC50 of 25 µM .
    VEGFR-2-IN-42
  • HY-149024

    VEGFR Apoptosis MDM-2/p53 Cancer
    VEGFR-2-IN-23 (compound 11b) is a potent and selective VEGFR-2 inhibitor with an IC50 value of 0.34 nM. VEGFR-2-IN-23 shows antitumor activity. VEGFR-2-IN-23 induces apoptosis and cell cycle arrest at G1 phase .
    VEGFR-2-IN-23
  • HY-112337

    VEGFR PDGFR Cancer
    VEGFR-2-IN-44 (compound 4b) is a selective VEGF-R2 (Flk-1) inhibitor with an IC50 value of 70 nM. VEGFR-2-IN-44 also inhibits PDGF-Rβ with an IC50 of 920 nM .
    VEGFR-2-IN-44
  • HY-146367

    VEGFR Apoptosis Reactive Oxygen Species Cancer
    VEGFR-2-IN-19 (Compound 15b) is a potent VEGFR2 inhibitor. VEGFR-2-IN-19 induces cell apoptosis and increases intracellular reactive oxygen species level. VEGFR-2-IN-19 can be used as an anticancer agent .
    VEGFR-2-IN-19
  • HY-144796

    VEGFR Apoptosis Cancer
    VEGFR-2-IN-15 (Compound 14b) is a potent VEGFR-2 inhibitor. VEGFR-2-IN-15 arrests the HepG2 cell growth at the Pre-G1 phase and induces apoptosis .
    VEGFR-2-IN-15
  • HY-149361

    VEGFR Inflammation/Immunology
    VEGFR2-IN-4 (compound 25) is a potent and selective VEGFR2 kinase inhibitor, with a GI50 of 0.7 nM. VEGFR2-IN-4 shows anti-angiogenic effect. VEGFR2-IN-4 can be used for the research of rheumatoid arthritis .
    VEGFR2-IN-4
  • HY-155610

    VEGFR Cancer
    VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2 with an IC50 of 8.93 nM. VEGFR-2-IN-32 has cytotoxic activity against PC-3 cells with an IC50 of 1.22 μM. VEGFR-2-IN-32 can be used for anti-prostate cancer research .
    VEGFR-2-IN-32
  • HY-157546

    VEGFR Interleukin Related Caspase Inflammation/Immunology Cancer
    VEGFR-2-IN-40 is a VEGFR-2 inhibitor. VEGFR-2-IN-40 boosts early and late apoptosis. VEGFR-2-IN-40 decreases the levels immunomodulatory proteins TNF-α and IL-6 while showing a four-fold rise in an apoptotic marker caspase-3 .
    VEGFR-2-IN-40
  • HY-P9920A

    VEGFR Cancer
    Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
    Ramucirumab (anti-VEGFR)
  • HY-155609

    VEGFR Cancer
    VEGFR-2-IN-31 (compound 3i) is a potent VEGFR-2 inhibitor (IC50=8.93 nM), and an anti-prostate cancer agent. VEGFR-2-IN-31 arrests cell cycle at the S-phase and induces apoptosis.
    VEGFR-2-IN-31
  • HY-149512

    FGFR VEGFR Cancer
    FGFR1/VEGFR2-IN-1 (compound 2b) is an FGFR1/VEGFR2 inhibitor. FGFR1/VEGFR2-IN-1 can be used for cancer research .
    FGFR1/VEGFR2-IN-1
  • HY-144754

    VEGFR Apoptosis Cancer
    VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor with an IC50 of 3.4 nM. VEGFR-2-IN-13 disrupts the HepG2 cell cycle by arresting the G2/M phase and induces apoptosis .
    VEGFR-2-IN-13
  • HY-132305

    VEGFR Cancer
    VEGFR-3-IN-1 is a potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth .
    VEGFR-3-IN-1
  • HY-18625

    VEGFR Cancer
    VEGFR-2-IN-5 is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69 .
    VEGFR-2-IN-5
  • HY-18625A

    VEGFR Cancer
    VEGFR-2-IN-5 hydrochloride is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69 .
    VEGFR-2-IN-5 hydrochloride
  • HY-P990106

    VEGFR Cancer
    Anti-Mouse VEGFR-2 Antibody (DC101) is a potent VEGFR2 inhibitor that can be used for the research of papilloma .
    Anti-Mouse VEGFR-2 Antibody (DC101)
  • HY-160259

    PROTACs VEGFR Cardiovascular Disease
    VEGFR-2-IN-39 (PROTAC-5) is a PROTAC targeting VEGFR-2 (IC50: 208.6 nM). VEGFR-2-IN-39 has low toxicity.VEGFR-2-IN-39 inhibits the proliferation of EA.hy926, one of HUVECs, in a concentration-dependent manner, with an IC50 of 38.65 µM .
    VEGFR-2-IN-39
  • HY-146492

    VEGFR Raf Apoptosis Cancer
    VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual VEGFR-2 and BRAF kinases inhibitor with IC50 values of 0.111, 0.089 and 0.071 µM against VEGFR-2, BRAF V600E and BRAF WT, respectively. VEGFR-2/BRAF-IN-2 induces apoptosis and arrests the cell cycle mainly in the G1 phase .
    VEGFR-2/BRAF-IN-2
  • HY-155760

    VEGFR Carbonic Anhydrase Cancer
    hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC50=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells .
    hCA/VEGFR-2-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: